When Vince Young, OD introduced the Daytona from Optos in his practice, he volunteered to be the imaging guinea pig while his staff was being trained on the device. He was unnerved when he reviewed his images with the trainer and somewhat uncertain about what he was actually seeing. He knew what a posterior subcapsular cataract (PSC) looked like through the slit lamp but was surprised by what the optomap image laid evident. While optomap is known for being able to penetrate through medial opacities far better than white light modalities, a PSC, which tends to be denser than other types of cataract, will cast a shadow on the retina revealing the issue. A concerned Dr. Young sent the image to his wife, Lindsey Brewer Young, OD. When she reviewed the image on her phone she immediately responded, questioning whose eye she was regarding. Learning it was her husband’s image she returned to the clinic, conducted a dilated exam, and confirmed that it was indeed a PSC that had been revealed in the optomap image.
As a private practice optometric physician and professor of optometry near Portland, Oregon, Lorne Yudcovitch, OD had the opportunity to experience optomap technology on a frequent basis for nearly a decade, both in the clinical setting and as a tool for instructing his students. While he valued the ultra-widefield view and the innovative capabilities, he did not purchase an Optos device until 2012.
“I felt that the optomap technology had improved not only in resolution, but it was more user-friendly, making it much easier to position the patient – and we loved the autofluorescence modality. That has become really invaluable.” Yudcovitch explained how optomap Daytona can quickly and easily reveal issues that might otherwise go unnoticed.
He describes a recent scenario when Lila, a 54-year-old Caucasian female, came to the clinic with night vision complaints. Yudcovitch shares that she was correctable to 20/20 vision in each eye and that he found no retinal abnormalities with conventional imaging and ophthalmoscopy. However, the optomap af image revealed significant hyper and hypo fluorescence mottling in the posterior pole in both eyes. Yudcovitch immediately referred her for further retinal examination and genetic testing which revealed a hereditary PRPH2 gene mutation variant.
The leaders in ultra-widefield (UWF™) retinal imaging technology, Optos, invite you to join us at Vision Expo East (VEE) March 15–18 in NYC.
Find out what’s new at Optos by pre-scheduling your demonstration or stop by our booth. Learn about our devices, software and imaging modalities that can help you diagnose and treat more ocular and systemic disease. Throughout the show, Optos will be at booth MS4849. Be our guest in the exhibit hall at VEE 2018 by clicking this link to receive your complimentary pass.
Getting in early? Join us, Thursday, March 15th at the Lambs Club at 6:30 pm for our Clinical Insights on AMD panel discussion, moderated by Dr. Jeff Gerson, FAAO.
Key topics include: • The epidemiology of AMD and the global burden of the disease • Combining traditional retinal exam methods with new technologies to facilitate early AMD detection • How to customize treatment plans for patients with exudative and non-exudative AMD • Implementing evidence-based nutritional management when appropriate • The roles of macular pigment optical density testing, OCT, and dark adaptometry in building a retina/AMD practice